| Groupa | P-value | ||
---|---|---|---|---|
I (n = 33) | II (n = 30) | III (n = 29) | ||
UICC stage III, n | 10 | 8 | 8 | Â |
UICC stage IV, n | 23 | 22 | 21 | Â |
UICC stage IVa, n | 19 | 20 | 18 | Â |
UICC stage IVb, n | 4 | 2 | 3 | Â |
Primary tumor n (%)b | Â | Â | Â | Â |
 CR | 16 (48.5) | 5 (16.7)d | 5 (17.2)d | 0.006b |
 UICC stage III | 6 (60.0) | 2 (25.0) | 1 (12.5) | 0.098 |
 UICC stage IV | 10 (43.5) | 3 (13.6) | 4 (19.0) | 0.051 |
 PR | 11 (33.3) | 11 (36.7) | 10 (34.5) | 0.961 |
 UICC stage III | 2 (20.0) | 3 (37.5) | 4 (50.0) | 0.450 |
 UICC stage IV | 9 (39.1) | 8 (36.4) | 6 (28.6) | 0.572 |
 SD or PD | 6 (18.2%) | 14 (46.7)d | 14 (48.3)d | 0.020b |
 UICC stage III | 2 (20.0) | 3 (37.5) | 3 (37.5) | 0.645 |
 UICC stage IV | 4 (17.4) | 11 (50.0)d | 11 (50.0)d | 0.028b |
 Recurrence | 3 (9.1) | 6 (20.0) | 7 (24.1) | 0.267 |
 Death | 16 (48.5) | 20 (66.7) | 22 (75.9) | 0.050 |
Side effects, n (%)c | Â | Â | Â | Â |
 Flu-like symptoms | 27 (81.8%) | 23 (76.7%) | 16 (55.2) | 0.051 |
 UICC stage III | 9 (90.0%) | 4 (50.0%) | 4 (50.0%) | 0.113 |
 UICC stage IV | 18 (78.3%) | 19 (86.4%) | 12 (57.1%) | 0.078 |
 Bone marrow suppression | 12 (36.4%) | 0 (0.0%) | 11 (37.9%) | 0.001c |
 UICC stage III | 2 (20.0%) | 0 (0.0%) | 2 (25.0%) | 0.506 |
 UICC stage IV | 10 (43.5%) | 0 (0.0%) | 9 (42.9%) | 0.001c |